New AI-Driven Planning Platform Designed to Unlock a New Class of Disease-Modifying Therapies for CNS Disorders
Brainlab SE, a global digital medical technology company specializing in AI-driven clinical workflow robotization, has launched a strategic cooperation with Precision NeuroMed (PNM), a clinical-stage biotechnology company focused on precision medicine for central nervous system (CNS) conditions. The collaboration aims to develop and manipulate an AI-enabled treatment planning platform designed to enhance convection-enhanced delivery (CED) curatives directly into the brain tumor.
The cooperation represents a significant advancement in AI in healthcare and perfection, targeting one of the biggest challenges in neurological treatment – the blood-brain barrier. This natural hedge frequently prevents systemically administered medicines from reaching therapeutic levels within the brain, limiting the effectiveness of treatments for severe neurological conditions. Convection-enhanced delivery addresses this limitation by enabling targeted medicine infusion directly into the brain tissue, allowing precise delivery of large-patch rectifiers while minimizing systemic exposure and implicit side effects.
Health Technology Insights: https://healthtechnologyinsights.com/amazon-goes-all-in-on-affordable-healthcare-with-automatic-drug-savings/
By combining Brainlab’s moxie in medical imaging digitalization, surgical workflow integration, and perfect treatment planning with Precision NeuroMed’s personal molecular inflow simulation technology, the companies plan to develop a patient-centered CED Treatment Planning System(CED TPS). The platform will use advanced imaging technologies, simulation modeling, and AI- driven optimization to epitomize medicine delivery strategies for individual cases, perfecting treatment perfection and reproducibility.
The collaboration will operate under a Joint Development and Commercialization Agreement. As part of the cooperation, Brainlab has also entered an equity stake in Precision NeuroMed, reflecting a participating commitment to accelerating invention and expanding the clinical application of targeted brain curatives.
Rainer Birkenbach, Chief Executive Officer of Brainlab SE, stressed the strategic alignment between the two associations. He explained that the cooperation combines Brainlab’s experience in developing advanced medical software with Precision NeuroMed’s focus on enabling targeted remedial delivery for complex neurological conditions. The thing is to give clinicians advanced planning tools that enhance surgical confidence and improve the effectiveness of treatments for grueling brain diseases.
Sandeep Kunwar, CEO and Co-Founder of Precision NeuroMed, highlighted the importance of combining foundational (birth) innovation with AI-based treatment planning. According to Kunwar, new brain disease treatments have long been hindered by difficulties in delivering drugs to exact brain regions. By merging artificial intelligence with computer simulation of molecules, the companies intend to establish a new benchmark for highly customized, accurate, and consistent (reproducible) neurological treatments.
The original phase of development will concentrate on supporting PNM’s lead investigational remedy, PNM- 201, designed to treat intermittent glioblastoma, one of the most aggressive and fatal forms of brain cancer. Over time, the companies plan to expand the platform’s capabilities to support fresh curatives, including gene-grounded treatments for conditions such as epilepsy, Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis(ALS).
By integrating AI-powered simulation with advanced medical imaging and clinical workflow tools, the Brainlab–Precision NeuroMed collaboration aims to standardize and optimize precision medicine delivery to the brain. This initiative could expand access to innovative neurological treatments across specialized hospitals and community treatment centers, addressing the needs of patients with complex and underserved neurological diseases.
Health Technology Insights: https://healthtechnologyinsights.com/ethical-dilemmas-of-implementing-artificial-intelligence-in-medicine/
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
